Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 25 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 25, 2023, titled "Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases